[go: up one dir, main page]

SI1848727T1 - Polimorf b ibandronata - Google Patents

Polimorf b ibandronata

Info

Publication number
SI1848727T1
SI1848727T1 SI200631955T SI200631955T SI1848727T1 SI 1848727 T1 SI1848727 T1 SI 1848727T1 SI 200631955 T SI200631955 T SI 200631955T SI 200631955 T SI200631955 T SI 200631955T SI 1848727 T1 SI1848727 T1 SI 1848727T1
Authority
SI
Slovenia
Prior art keywords
ibandronate polymorph
ibandronate
polymorph
Prior art date
Application number
SI200631955T
Other languages
English (en)
Inventor
Uwe Eiermann
Bernd Junghans
Bernhard Knipp
Tim Sattelkau
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36088250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1848727(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI1848727T1 publication Critical patent/SI1848727T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
SI200631955T 2005-02-01 2006-01-24 Polimorf b ibandronata SI1848727T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100687 2005-02-01
PCT/EP2006/000579 WO2006081962A1 (en) 2005-02-01 2006-01-24 Ibandronate polymorph b
EP06701843.2A EP1848727B1 (en) 2005-02-01 2006-01-24 Ibandronate polymorph b

Publications (1)

Publication Number Publication Date
SI1848727T1 true SI1848727T1 (sl) 2015-09-30

Family

ID=36088250

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631955T SI1848727T1 (sl) 2005-02-01 2006-01-24 Polimorf b ibandronata

Country Status (20)

Country Link
US (2) US7582789B2 (sl)
EP (3) EP2363401A1 (sl)
JP (2) JP5828607B2 (sl)
KR (1) KR100908530B1 (sl)
CN (1) CN101111505B (sl)
AR (1) AR053119A1 (sl)
AU (1) AU2006210008B2 (sl)
BR (1) BRPI0607093A2 (sl)
CA (1) CA2594717C (sl)
DK (1) DK1848727T3 (sl)
ES (1) ES2543804T3 (sl)
IL (1) IL184720A (sl)
MX (1) MX2007008917A (sl)
NO (1) NO20073755L (sl)
PL (1) PL1848727T3 (sl)
RU (1) RU2387661C2 (sl)
SI (1) SI1848727T1 (sl)
TW (1) TWI374888B (sl)
WO (1) WO2006081962A1 (sl)
ZA (1) ZA200706170B (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070043043A (ko) 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
AU2006210008B2 (en) * 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
PT103600B (pt) * 2006-11-06 2009-01-30 Hovione Farmaciencia Sa Processo para a preparação de ácidos biosfónicos e seus sais farmaceuticamente aceitáveis
EP1966227A1 (en) * 2006-11-16 2008-09-10 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2144919B1 (en) * 2007-04-11 2015-12-02 F. Hoffmann-La Roche AG Multi step synthesis of ibandronate
EP2134731A1 (en) 2007-04-19 2009-12-23 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201200588A2 (tr) 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764604A (en) * 1968-12-17 1973-10-09 Us Army 4-pyridylcarbinolamine anti-malarials
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (sl) * 1988-11-28 1993-01-11 Ciba Geigy Ag
IL98764A0 (en) * 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
DE19531264A1 (de) * 1995-08-25 1997-02-27 Hoechst Ag Kationische, ungesättigte Saccharide sowie daraus hergestellte Polymerisate und deren Verwendung
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
TW577893B (en) 1998-10-16 2004-03-01 Akzo Nobel Nv High purity composition comprising (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
WO2000033849A1 (en) * 1998-12-04 2000-06-15 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
WO2001075080A1 (en) * 2000-03-30 2001-10-11 Research Development Foundation Tyr393 and tyr398 mutants of monoamine oxidase b
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
CA2763775C (en) * 2002-05-10 2014-01-07 F. Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
AU2006210008B2 (en) 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
PT2662380T (pt) 2005-02-01 2019-02-27 Atnahs Pharma Uk Ltd Utilização médica de polimorfo a de ibandronato

Also Published As

Publication number Publication date
CA2594717C (en) 2015-01-20
EP1848727A1 (en) 2007-10-31
EP1848727B1 (en) 2015-06-17
AU2006210008A1 (en) 2006-08-10
JP2008531480A (ja) 2008-08-14
CN101111505A (zh) 2008-01-23
NO20073755L (no) 2007-08-28
AU2006210008B2 (en) 2009-10-08
BRPI0607093A2 (pt) 2009-08-04
CA2594717A1 (en) 2006-08-10
RU2007132700A (ru) 2009-03-10
MX2007008917A (es) 2007-08-21
TWI374888B (en) 2012-10-21
IL184720A0 (en) 2007-12-03
ES2543804T3 (es) 2015-08-24
KR100908530B1 (ko) 2009-07-20
EP2363401A1 (en) 2011-09-07
IL184720A (en) 2014-12-31
DK1848727T3 (da) 2015-07-20
AR053119A1 (es) 2007-04-25
RU2387661C2 (ru) 2010-04-27
US20090312289A1 (en) 2009-12-17
KR20070100395A (ko) 2007-10-10
JP2015205908A (ja) 2015-11-19
US7582789B2 (en) 2009-09-01
US20060172976A1 (en) 2006-08-03
EP2610261A1 (en) 2013-07-03
WO2006081962A1 (en) 2006-08-10
JP6039755B2 (ja) 2016-12-07
ZA200706170B (en) 2008-09-25
CN101111505B (zh) 2011-09-14
PL1848727T3 (pl) 2015-11-30
TW200640940A (en) 2006-12-01
JP5828607B2 (ja) 2015-12-09

Similar Documents

Publication Publication Date Title
ZA200706170B (en) Ibandronate polymorph B
GB0602424D0 (en) Compounds
ZA200706168B (en) Ibandronate polymorph A
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
GB0605786D0 (en) Compounds
EP2082022A4 (en) COMPOUNDS
GB0504314D0 (en) Novel polymorph
GB0605785D0 (en) Compounds
GB0605784D0 (en) Compounds
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0602042D0 (en) Compounds
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP1973905A4 (en) COMPOUNDS
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
GB0601505D0 (en) Compounds
GB0605589D0 (en) Compounds
GB0602040D0 (en) Compounds
GB0604375D0 (en) Compounds
GB0602134D0 (en) Compounds
GB0600426D0 (en) Compounds
GB0602451D0 (en) Compounds
GB0602454D0 (en) Compounds